By Ana Espino | Published on october 7, 2025 | 3 min read
#Oncology #Eugenol #Phenol
Cancer is one of the leading causes
of death worldwide, characterized by
uncontrolled cell proliferation,
metastasis, and
resistance to treatment. Despite progress in targeted therapies
and
immunotherapy, current treatments often remain
toxic, costly, and
associated with a
reduced quality of life. The main challenge, therefore, is to
discover
safer anticancer agents that can effectively target tumor cells while
sparing healthy tissues.
In this context, eugenol, a
natural phenolic compound derived from clove (Syzygium aromaticum), has
generated growing interest. With antioxidant, anti-inflammatory, and
antiproliferative properties, it appears to be a promising candidate for
the development of alternative anticancer therapies.
This study aimed to
highlight the mechanisms of action of eugenol, its molecular targets,
pharmacological profile, and current limitations in view of
possible clinical applications.
Cell killer or simple antioxidant?
Among the studies analyzed, a large
selection of in vitro, in vivo, and preclinical research
was included, focusing on the evaluation of eugenol’s effects on various types
of cancer—particularly breast, colon, prostate, lung, liver, skin, and oral
tumors. The selected research was chosen for its experimental quality,
including analyses of molecular mechanisms of action, involved
signaling pathways, as well as pharmacokinetic and toxicological
parameters.
The results show that eugenol
inhibits tumor proliferation by modulating the expression of pro-apoptotic
genes (Bax, p53) and reducing that of survival genes (Bcl-2,
survivin). It induces mitochondrial apoptosis, blocks cell
cycle progression, and inhibits signaling pathways such as NF-κB, PI3K/Akt/mTOR, and MAPK, all of
which play major roles in tumor progression.
Eugenol also affects cell
migration, angiogenesis, and sensitizes certain cancer cells to
conventional treatments. Moreover, eugenol displays a favorable
pharmacological profile (low toxicity, acceptable bioavailability), but
remains limited by poor solubility, chemical instability, and a
lack of suitable clinical formulations. Nanotechnological approaches
are currently being explored to overcome these barriers.
A small phenol with big ambitions
Cancer, a multifactorial disease
with complex mechanisms, continues to be one of the leading causes of death
worldwide. Although current treatments are more targeted, they are still
associated with high toxicity, frequent therapeutic resistance,
and compromised quality of life.
In this context, this review aimed
to explore the anticancer potential of eugenol, a natural compound with
multiple pharmacological properties.
The results suggest that eugenol
exhibits promising antitumor activity, acting on cell proliferation,
apoptosis, migration, and angiogenesis, while modulating key cell
signaling pathways. Its low toxicity and reasonable
bioavailability make it a serious candidate for integrative therapeutic
approaches.
However, the study also highlights
the need for further research, including standardized preclinical studies,
early-phase clinical trials, and the development of optimized
formulations (notably using nanocarriers) to improve stability and
tumor targeting. Combining eugenol with other treatments, or incorporating it
into adjuvant protocols, could pave the way for more effective, less
toxic, and better-personalized anticancer therapies.
Read next: Breast cancer: could the key lie in our diet and our bacteria?
About the author – Ana EspinoPhD in Immunology, specialized in Virology
